Century Therapeutics, Inc.

NasdaqGS:IPSC Stock Report

Market Cap: US$237.3m

Century Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Century Therapeutics has a total shareholder equity of $184.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $360.7M and $175.9M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$172.74m
EquityUS$184.75m
Total liabilitiesUS$175.94m
Total assetsUS$360.69m

Recent financial health updates

Recent updates

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06
Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Feb 01

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Aug 25

Financial Position Analysis

Short Term Liabilities: IPSC's short term assets ($177.0M) exceed its short term liabilities ($17.8M).

Long Term Liabilities: IPSC's short term assets ($177.0M) exceed its long term liabilities ($158.1M).


Debt to Equity History and Analysis

Debt Level: IPSC is debt free.

Reducing Debt: IPSC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPSC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IPSC is forecast to have sufficient cash runway for 12 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.